Recce Pharmaceuticals (RCE.AX) Stock Price

Recce Pharmaceuticals Price

ASX·CLOSED
0.33
-0.0000 (-0.00 %)
Market closed

Over the last 12 years Recce Pharmaceuticals grew revenue by 127.7% annually, reaching 7.51 M AUD. For Recce Pharmaceuticals, the net margin of -285.4% is up versus -825.3% a few years ago. The stock trades about 3% above its 52-week low.

Recce Pharmaceuticals stock price

Access this data via the Eulerpool API

Recce Pharmaceuticals business model & stock analysis

Frequently asked questions about Recce Pharmaceuticals

Converted at the current exchange rate, the Recce Pharmaceuticals share trades at 0.20 EUR (0.33 AUD).

The Recce Pharmaceuticals share (RCE.AX) is listed on 3 stock exchanges, including: ASX (RCE.AX), Frankfurt (R9Q.F), München (R9Q.MU).

No history available for Recce Pharmaceuticals.

The revenue cannot currently be calculated for Recce Pharmaceuticals.

The profit of Recce Pharmaceuticals is -14.96 M AUD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Recce Pharmaceuticals is currently -6.38. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Recce Pharmaceuticals stock.

The P/S cannot be calculated for Recce Pharmaceuticals currently.

The Eulerpool Quality Score for Recce Pharmaceuticals is 2/10.

The ISIN of Recce Pharmaceuticals is AU000000RCE5. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Recce Pharmaceuticals is A2ADQM. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Recce Pharmaceuticals is RCE.AX. The ticker symbol is used to trade Recce Pharmaceuticals shares on the stock exchange.

Recce Pharmaceuticals paid dividends every year for the past 0 years.

Recce Pharmaceuticals is assigned to the 'Health' sector.

The dividends of Recce Pharmaceuticals are distributed in AUD.

Fair ValueTerminal
0.27 AUD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website recce.com.au
Country
Australia
Currency
AUD
Initial public offering
Jan 15, 2016
ISIN
AU000000RCE5
Cusip
Q8052V103
Market capitalization
95.43 M AUDMicro Cap
52-Week Range
0.32–0.70AUD
Revenue growth (10Y) > 5%
Revenue growth (3Y) > 5 %
EBIT growth (10Y) > 5%
EBIT growth (3Y) > 5 %
Net debt < 4x EBIT
Profitable since 10Y+
EBIT Drawdown (10Y) < 50%
Return on Equity (ROE) > 15%
ROCE > 15%
Return Expectation > 10%
PEG
—
P/E ratio
P/Ee 2027
-3.88
P/Ee 2028
2.97
P/Se
10.79
EV/EBIT
—
P/B Ratio
9.48
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
238.19 %
Gross Margin
—
EBIT Margin
—
Net Margin
—
EPS (Earnings Per Share)
-0.05 AUD
Net Debt / EBIT
-0.35
Debt/Equity
-0.62
Last updated Sep 27, 2026, 8:08 PM

Recce Pharmaceuticals Peer Group

Recce Pharmaceuticals Ticker

ASX · RCE.AXFRANKFURT · R9Q.FMUNICH · R9Q.MU

Recce Pharmaceuticals FIGI

RCE:AU · BBG009XWNPF6RCE:AT · BBG009XWNPG5RCE:AH · BBG009XWNPL9RECEF:US · BBG00RHNFXV8RECEF:PQ · BBG00RHNFY82RECEF:UV · BBG00RHNFY91R9Q:GR · BBG00TX25HN7R9Q:GF · BBG00TX25HQ4R9Q:GS · BBG00TX25HV8R9Q:GM · BBG00TX25HW7R9Q:GB · BBG00TX25HX6RCEEUR:XS · BBG00TYNXKG0